ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are admi...

Full description

Saved in:
Bibliographic Details
Main Authors IRIZARRY, Michael Carl, DEMATTOS, Ronald Bradley
Format Patent
LanguageEnglish
French
German
Published 10.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.
Bibliography:Application Number: EP20230176986